AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira; A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived

Taking stock of the drug industry, from the lab to the medicine chest

February 20, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jacquelyn Martin/AP STAT+ | AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira AbbVie leader Richard Gonzalez should be a sobering reminder to the drug industry's critics of how resilient a CEO's reputation can be. By Matthew Herper STAT+ | A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived The case stems from a troubling episode involving a Sanofi subsidiary, which, at one point, sold the only drug for Fabry disease in the U.S. By Ed Silverman STAT+ | Obamacare plans don't have to cover weight loss drugs. The government is considering changing that GLP-1 obesity drugs like Wegovy, Zepbound under consideration for coverage by Affordable Care Act administrators; public comment requested. By John Wilkerson University of Pittsburgh Phage therapy: Researchers sharpen another arrow in the quiver against antibiotic resistance Widespread adoption of phage therapy is seen as a much-needed antidote to the growth of antimicrobial drug resistance. By Deborah Balthazar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser